Biolistic-mediated interleukin 4 gene transfer prevents the onset of Type 1 diabetes

Human Gene Therapy

Volumn 11, Issue 12, 2000, Pages 1647-1656

  Cameron, Mark J ^a,b   Strathdee, Craig A ^a,b   Holmes, Kevin D ^a,b   Arreaza, Guillermo A ^a,b   Dekaban, Gregory A ^a,b   Delovitch, Terry L ^a,b  

^a ROBARTS RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN HERPESVIRUS 4; MURINAE;

COMPLEMENTARY DNA; CYTOKINE; IMMUNOGLOBULIN E; INTERLEUKIN 4;

ANIMAL; ARTICLE; BIOLISTIC TRANSFORMATION; BLOOD; EPSTEIN BARR VIRUS; FEMALE; FLOW CYTOMETRY; GENE VECTOR; GENETICS; INSULIN DEPENDENT DIABETES MELLITUS; METABOLISM; MOUSE; NONOBESE DIABETIC MOUSE; PANCREAS; PATHOLOGY; SECRETION; T LYMPHOCYTE;

ANIMALS; BIOLISTICS; CYTOKINES; DIABETES MELLITUS, TYPE 1; DNA, COMPLEMENTARY; FEMALE; FLOW CYTOMETRY; GENETIC VECTORS; HERPESVIRUS 4, HUMAN; IMMUNOGLOBULIN E; INTERLEUKIN-4; MICE; MICE, INBRED NOD; PANCREAS; T-LYMPHOCYTES;

EID: 0034632361     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/10430340050111304     Document Type: Article

References (33)

1. ARREAZA, G.A., CAMERON, M.J., JARAMILLO, A., GILL, B.M., HARDY, D., LAUPLAND, K.B., RAPOPORT, M.J., ZUCKER, P., CHAKRABARTI, S., CHENSUE, S.W., QIN, H.Y., SINGH, B., and DELOVITCH, T.L. (1997). Neonatal activation of CD28 signaling overcomes T cell anergy and prevents autoimmune diabetes by an IL-4-dependent mechanism. J. Clin. Invest. 100, 2243-2253.
2. BERGEROT, I., ARREAZA, G.A., CAMERON, M.J., BURDICK, M.D., STRIETER, R.M., CHENSUE, S.W., CHAKRABARTI, S., and DELOVITCH, T.L. (1999). Insulin B-chain reactive CD4+ regulatory T-cells induced by oral insulin treatment protect from type 1 diabetes by blocking the cytokine secretion and pancreatic infiltration of diabetogenic effector T-cells. Diabetes 48, 1720-1729.
3. BLAKE, N., LEE, S., REDCHENKO, I., THOMAS, W., STEVEN, N., LEESE, A., STEIGERWALD-MULLEN, P., KURILLA, M.G., FRAPPIER, L., and RICKINSON, A. (1997). Human CD8+ T cell responses to EBV ENBA1: HLA class I presentation of the (Gly-Ala)-containing protein requires exogenous processing. Immunity 7, 791-802.
4. BOCHKAREV, A., BARWELL, J.A., PFUETZNER, R.A., FUREY, W.J., EDWARDS, A.M., and FRAPPIER, L. (1995). Crystal structure of the DNA-binding domain of the Epstein-Barr virus origin-binding protein EBNA 1. Cell 83, 39-46.
5. CAMERON, M.J., ARREAZA, G.A., ZUCKER, P., CHENSUE, S.W., STRIETER, R.M., CHAKRABARTI, S., and DELOVITCH, T.L. (1997). IL-4 prevents insulitis and insulin-dependent diabetes mellitus in nonobese diabetic mice by potentiation of regulatory T helper-2 cell function. J. Immunol. 159, 4686-4692.
6. DELOVITCH, T.L., and SINGH, B. (1997). The nonobese diabetic mouse as a model of autoimmune diabetes: Immune dysregulation gets the NOD. Immunity 7, 727-738.
7. EDWARDS, A.M., BOCHKAREV, A., and FRAPPIER, L. (1998). Origin DNA-binding proteins. Curr. Opin. Struct. Biol. 8, 49-53.
8. FOX, C.J., and DANSKA, J.S. (1998). Independent genetic regulation of T-cell and antigen-presenting cell participation in autoimmune islet inflammation. Diabetes 47, 331-338.
9. GALLICHAN, W.S., BALASA, B., DAVIES, J.D., and SARVET-NICK, N. (1999). Pancreatic IL-4 expression results in islet-reactive Th2 cells that inhibit diabetogenic lymphocytes in the nonobese diabetic mouse. J. Immunol. 163, 1696-1703.
10. GROGER, R.K., MORROW, D.M., and TYKOCINSKI, M.L. (1989). Directional antisense and sense cDNA cloning using Epstein-Barr virus episomal expression vectors. Gene 81, 285-294.
11. HOLLON, T. (2000). Researchers and regulators reflect on first gene therapy death. Nature Med. 6, 6.
12. KHANNA, R., BURROWS, S.R., STEIGERWALD-MULLEN, P.M., MOSS, D.J., KURILLA, M.G., and COOPER, L. (1997). Targeting Epstein-Barr virus nuclear antigen 1 (EBNA1) through the class II pathway restores immune recognition by EBNA1-specific cytotoxic T lymphocytes: Evidence for HLA-DM-independent processing. Int. Immunol. 9, 1537-1543.
13. LEVITSKAYA, J., CORAM, M., LEVITSKY, V., IMREH, S., STEIGERWALD-MULLEN, P.M., KLEIN, G., KURILLA, M.G., and MASUCCI, M.G. (1995). Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1. Nature (London) 375, 685-688.
14. LEVITSKAYA, J., SHARIPO, A., LEONCHIKS, A., CIECHANOVER, A., and MASUCCI, M.G. (1997). Inhibition of ubiquitin/proteasome-dependent protein degradation by the Gly-Ala repeat domain of the Epstein-Barr virus nuclear antigen 1. Proc. Natl. Acad. Sci. U.S.A. 94, 12616-12621.
15. MIDDLETON, T., and SUGDEN, B. (1994). Retention of plasmid DNA in mammalian cells is enhanced by binding of the Epstein-Barr virus replication protein EBNA1. J. Virol. 68, 4067-4071.
16. NITTA, Y., TASHIRO, F., TOKUI, M., SHIMADA, A., TAKEI, I., TABAYASHI, K., and MIYAZAKI, J. (1998). Systemic delivery of interleukin 10 by intramuscular injection of expression plasmid DNA prevents autoimmune diabetes in nonobese diabetic mice. Hum. Gene Ther. 9, 1701-1707.
17. PICCIRILLO, C.A., CHANG, Y., and PRUD'HOMME, G.J. (1998). TGF-beta1 somatic gene therapy prevents autoimmune disease in nonobese diabetic mice. J. Immunol. 161, 3950-3956.
18. PILSTROM, B., BJORK, L., and BOHME, J. (1995). Demonstration of a TH1 cytokine profile in the late phase of NOD insulitis. Cytokine 7, 806-814.
19. PRUD'HOMME, G.J., and CHANG, Y. (1999). Prevention of autoimmune diabetes by intramuscular gene therapy with a nonviral vector encoding an interferon-gamma receptor/IgG1 fusion protein. Gene Ther. 6, 771-777.
20. RABINOVITCH, A., SUAREZ-PINZON, W.L., SORENSEN, O., BLEACKLEY, R.C., and POWER, R.F. (1995). IFN-gamma gene expression in pancreatic islet-infiltrating mononuclear cells correlates with autoimmune diabetes in nonobese diabetic mice. J. Immunol. 154, 4874-4882.
21. RAPOPORT, M.J., JARAMILLO, A., ZIPRIS, D., LAZARUS, A.H., SERREZE, D.V., LEITER, E.H., CYOPICK, P., DANSKA, J.S., and DELOVITCH, T.L. (1993). Interleukin 4 reverses T cells proliferative unresponsiveness and prevents the onset of diabetes in nonobese diabetic mice. J. Exp. Med. 178, 87-99.
22. RYAN, J.J. (1997). Interleukin-4 and its receptor: essential mediators of the allergic response. J. Allergy Clin. Immunol. 99, 1-5.
23. SHEHADEH, N.N., LAROSA, F., and LAFFERTY, K.J. (1993). Altered cytokine activity in adjuvant inhibition of autoimmune diabetes. J. Autoimmun. 6, 291-300.
24. STAVROPOULOS, T.A., and STRATHDEE, C.A. (2000). Stable gene transfer using herpes Simplex virus-Epstein-Barr virus hybrid amplicon vectors. In Viral Vectors: Basic Science and Gene Therapy. A. Cid-Arregui and A. Garcia-Carranca, eds. (Eaton Publishing, Natick, MA) in press.
25. SU, W., MIDDLETON, T., SUGDEN, B., and ECHOLS, H. (1991). DNA looping between the origin of replication of Epstein-Barr virus and its enhancer site: Stabilization of an origin complex with Epstein-Barr nuclear antigen 1. Proc. Natl. Acad. Sci. U.S.A. 88, 10870-10874.
26. SUGDEN, B., MARSH, K., and YATES, J. (1985). A vector that replicates as a plasmid and can be efficiently selected in B-lymphoblasts transformed by Epstein-Barr virus. Mol. Cell Biol. 5, 410-413.
27. SUMMERS, H., BARWELL, J.A., PFUETZNER, R.A., EDWARDS, A.M., and FRAPPIER, L. (1996). Cooperative assembly of EBNA1 on the Epstein-Barr virus latent origin of replication. J. Virol. 70, 1228-1231.
28. TOMIYASU, K., SATOH, E., ODA, Y., NISHIZAKI, K., KONDO, M., IMANISHI, J., and MAZDA, O. (1998). Gene transfer in vitro and in vivo with Epstein-Barr virus-based episomal vector results in markedly high transient expression in rodent cells. Biochem. Biophys. Res. Commun. 253, 733-738.
29. VON HERRATH, M.G., and OLDSTONE, M.B. (1997). Interferongamma is essential for destruction of beta cells and development of insulin-dependent diabetes mellitus. J. Exp. Med. 185, 531-539.
30. WENDELBURG, B.J., and VOS, J.M. (1998). An enhanced EBNA1 variant with reduced IR3 domain for long-term episomal maintenance and transgene expression of oriP-based plasmids in human cells. Gene Ther. 5, 1389-1399.
31. YATES, J.L., and GUAN, N. (1991). Epstein-Barr virus-derived plasmids replicate only once per cell cycle and are not amplified after entry into cells. J. Virol. 65, 483-488.
32. YATES, J., WARREN, N., REISMAN, D., and SUGDEN, B. (1984). A cis-acting element from the Epstein-Barr viral genome that permits stable replication of recombinant plasmids in latently infected cells. Proc. Natl. Acad. Sci. U.S.A. 81, 3806-3810.
33. YATES, J.L., WARREN, N., and SUGDEN, B. (1985). Stable replication of plasmids derived from Epstein-Barr virus in various mammalian cells. Nature (London) 313, 812-815.